Gene editing experiment
Gene editing experiment

Fatal Gene-Editing Trial in China: Child Dead, Research Team Sacked

In November 2026, Chinese health and municipal authorities in Shanghai dismissed two prominent researchers and sanctioned several hospital officials following an official investigation into the death of a six-year-old girl during an experimental brain-directed gene-editing clinical trial. The case, which echoes earlier controversies in Chinese biomedical research, exposed severe ethical violations, overlooked preclinical safety warnings, undisclosed financial arrangements with the patient’s family, and the concealment of the child’s death in a high-profile scientific publication.

The tragedy centered on a six-year-old girl, identified in investigative reports under the pseudonym Mei, who suffered from Snijders Blok-Campeau syndrome. This rare neurodevelopmental disorder is caused by a specific mutation (R1025W) in the CHD3 gene, which leads to intellectual disabilities, speech delays, and distinct physical features, though individuals with the condition typically have a normal life expectancy. Seeking a cure, the girl’s parents approached Zilong Qiu, a well-known neuroscientist serving as deputy director of the Songjiang Research Institute affiliated with Shanghai Jiao Tong University School of Medicine, along with his collaborator Kan Yang, a researcher at the university-affiliated Xinhua Hospital. Qiu and his team were racing to develop a pioneering base-editing therapy—a precise form of CRISPR gene editing capable of chemically converting a single faulty DNA base into the correct one inside brain neurons without making double-stranded DNA breaks.

To make the experimental treatment possible, the research team entered into highly irregular financial arrangements with the child’s parents. Because developing and testing a bespoke viral vector and base editor is extraordinarily expensive, the family paid approximately 5.3 million yuan (over $800,000 USD) directly toward funding the research. Furthermore, official investigators later revealed that the parents gave the researchers roughly 1.06 million yuan in personal cash and gifts—including 900,000 yuan and liquor given to Kan Yang, and luxury liquor and electronics worth around 100,000 yuan given to Zilong Qiu. The parents later stated that they were never fully informed of the severe, life-threatening complications associated with the procedure or how unusual and dangerous these private funding arrangements were.

Before administering the therapy to the child, the researchers commissioned a preclinical safety study in non-human primates through a contract research organization. However, the hospital’s ethics committee approved the human clinical trial in January 2025 without reviewing the final primate toxicology report, which was only dated February 17, 2025. According to Shanghai authorities, Qiu’s team failed to properly inform Xinhua Hospital of potential safety signals and toxicity concerns identified during those primate tests. Despite these red flags, the team proceeded with the human trial in late March 2025, aiming to make the six-year-old the first person in the world to receive a brain-directed gene-editing therapy.

During the procedure at Xinhua Hospital, doctors injected an adeno-associated virus (AAV) vector carrying the base-editing machinery directly into the fluid at the base of the girl’s spine so it could reach her brain neurons. Soon after receiving the experimental infusion, the child suffered a catastrophic immune reaction. An emergency ethics review later attributed her death in March 2025 to thrombotic microangiopathy, a severe and known complication of high-dose viral vector gene therapies in which blood clots form in small blood vessels, leading to organ failure. Following her death, the hospital’s ethics committee immediately terminated the clinical study, and the hospital quietly paid a modest administrative fine to a local health authority without any public disclosure.

The cover-up deepened nearly a year later when, on February 18, 2026, Zilong Qiu, Kan Yang, and their colleagues published a major paper in the prestigious scientific journal Nature describing their base-editing approach for neurodevelopmental disorders. Remarkably, the research team concealed the girl’s death from the scientific community and omitted key details regarding the clinical trial’s fatal outcome and funding sources in their published manuscript. The truth only began to unravel in July 2026, when an investigative report by Science and Retraction Watch exposed the child’s death, the $800,000 payment from her parents, and the overlooked safety warnings.

Prompted by the international outcry, Shanghai municipal authorities launched a formal probe that culminated in sweeping disciplinary actions announced on November 13, 2026. Both Zilong Qiu and Kan Yang were formally sacked from their institutional positions, barred for five years from participating in government-funded science and technology programs or receiving scientific awards, and entered into China’s national database for serious breaches of research integrity. Investigators also confirmed that the 1.06 million yuan in cash and gifts accepted from the girl’s family had been returned.

Accountability extended to the hospital administrators who failed to oversee the trial. The clinical study’s lead investigator, surnamed Yu, was removed as head of Xinhua Hospital’s research department, demoted, and handed a five-year ban on promotions, research grants, awards, and recruiting graduate students. Another official, surnamed Shi, was stripped of his role as head of the hospital’s ethics committee office and demoted, while several other officials responsible for ethics review and research oversight received disciplinary sanctions alongside an administrative penalty against Xinhua Hospital itself.

In response to the scandal, the Shanghai Municipal Health Commission announced special inspections across institutions conducting clinical research on emerging biomedical technologies, warning researchers that rapid innovation in cell and gene therapies cannot come at the expense of strict ethical and safety standards. Legal and bioethics experts noted that the harsh penalties were intended to send a stark warning across China’s biomedical sector, which has worked for years to rebuild global trust following the 2018 scandal involving biophysicist He Jiankui and the world’s first gene-edited babies.